Gedif K[au] - Search Results

Year	Number of Results
2016	1
2017	1
2020	1
2021	4
2022	8

1

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG. Dugel PU, et al. Among authors: gedif k. Ophthalmology. 2021 Jan;128(1):89-99. doi: 10.1016/j.ophtha.2020.06.028. Epub 2020 Jun 20. Ophthalmology. 2021. PMID: 32574761 Free article. Clinical Trial.

2

Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.

Singh RP, Jhaveri C, Wykoff CC, Gale RP, Staurenghi G, Iida T, Koh A, B G, Gedif K, Singer M. Singh RP, et al. Among authors: gedif k. Ophthalmol Retina. 2022 May;6(5):377-386. doi: 10.1016/j.oret.2021.12.014. Epub 2021 Dec 27. Ophthalmol Retina. 2022. PMID: 34968756 Clinical Trial.

3

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.

Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, Lee WK, Chang AA, Monés J, D'Souza D, Weissgerber G, Gedif K, Koh A. Ogura Y, et al. Among authors: gedif k. Br J Ophthalmol. 2022 Jul;106(7):994-999. doi: 10.1136/bjophthalmol-2021-319090. Epub 2021 Jul 22. Br J Ophthalmol. 2022. PMID: 34301613 Free PMC article. Clinical Trial.

4

Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma.

Stahl E, Bremond-Gignac D, Landry T, Curtis M, Gedif K, Al Shahwan S, Dixon ER. Stahl E, et al. Among authors: gedif k. J Ocul Pharmacol Ther. 2017 Jun;33(5):361-365. doi: 10.1089/jop.2016.0133. Epub 2017 Feb 24. J Ocul Pharmacol Ther. 2017. PMID: 28437175 Clinical Trial.

5

Fluid control in neovascular age-related macular degeneration with brolucizumab: an analysis of the HAWK and HARRIER phase 3 trials.

Regillo C, Singh R, Hamilton R, Gedif K, Best C, Koh A, Holz FG. Regillo C, et al. Among authors: gedif k. Ophthalmologica. 2022 Apr 25. doi: 10.1159/000524096. Online ahead of print. Ophthalmologica. 2022. PMID: 35468601

6

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.

Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Lally DR, et al. Among authors: gedif k. Eye (Lond). 2022 Jun 8. doi: 10.1038/s41433-022-02130-2. Online ahead of print. Eye (Lond). 2022. PMID: 35676464 No abstract available.

7

Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data.

Jhaveri C, Wykoff CC, Khanani AM, Eandi CM, Chang A, B G, Gedif KA, Singer M. Jhaveri C, et al. Among authors: gedif ka. Am J Ophthalmol. 2022 Apr;236:12-19. doi: 10.1016/j.ajo.2021.10.017. Epub 2021 Oct 22. Am J Ophthalmol. 2022. PMID: 34695400 Free article.

8

Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.

Wilson ME, O'Halloran H, VanderVeen D, Roarty J, Plager DA, Markwardt K, Gedif K, Lambert SR. Wilson ME, et al. Among authors: gedif k. Eye (Lond). 2016 Sep;30(9):1187-94. doi: 10.1038/eye.2016.132. Epub 2016 Jul 1. Eye (Lond). 2016. PMID: 27367745 Free PMC article. Clinical Trial.

9

Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.

Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Lally DR, et al. Among authors: gedif k. Eye (Lond). 2022 May 21. doi: 10.1038/s41433-022-02092-5. Online ahead of print. Eye (Lond). 2022. PMID: 35597816

10

A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.

Poor SH, Weissgerber G, Adams CM, Bhatt H, Browning DJ, Chastain J, Ciulla TA, Ferriere M, Gedif K, Glazer LC, Joondeph BC, Normand G, Sheth V, Watters C, Grosskreutz CL. Poor SH, et al. Among authors: gedif k. Am J Ophthalmol. 2022 Jul;239:180-189. doi: 10.1016/j.ajo.2022.02.019. Epub 2022 Mar 2. Am J Ophthalmol. 2022. PMID: 35247334 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results